Proqr Therapeutics N V Quick Ratio (PRQR) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Proqr Therapeutics N v   (NASDAQ: PRQR)

Proqr Therapeutics N V 's Quick Ratio

PRQR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 2.85 a new company low.

Within Major Pharmaceutical Preparations industry 233 other companies have achieved higher Quick Ratio than Proqr Therapeutics N V in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 751 to 972.

Explain Quick Ratio?
How much Cash & cash equivalents PRQR´s has?
What are PRQR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRQR Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -16.61 % -16.61 % -16.61 % -16.61 % 13.74 %
Y / Y Cash & cash equivalent Change -38.15 % -38.15 % -38.15 % -38.15 % 25.63 %
Quick Ratio MRQ 2.85 2.85 2.85 2.85 3.84
PRQR's Total Ranking # 972 # 751 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -16.61 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -38.15 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 234
Healthcare Sector # 404
Overall Market # 972


Quick Ratio Statistics
High Average Low
10.49 5.33 2.85
(Dec 31 2018)   (Dec 31 2025)




Financial Statements
Proqr Therapeutics N V 's Current Liabilities $ 36 Millions Visit PRQR's Balance sheet
Proqr Therapeutics N V 's Cash & cash equivalent $ 104 Millions Visit PRQR's Balance sheet
Source of PRQR's Sales Visit PRQR's Sales by Geography


Cumulative Proqr Therapeutics N V 's Quick Ratio

PRQR's Quick Ratio for the trailling 12 Months

PRQR Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -16.61 % -9.73 % -2.85 % 4.91 % 13.2 %
Y / Y Cash & cash equivalent TTM Growth -38.15 % -24.77 % -9.88 % 6.81 % 25.63 %
Quick Ratio TTM 2.85 3.13 3.39 3.62 3.84
Total Ranking TTM # 4623 # 3497 # # #
Seq. Current Liabilities TTM Growth -4.74 % -4.53 % -4.33 % -4.15 % 3.11 %
Seq. Cash & cash equivalent TTM Growth -13.36 % -11.78 % -10.54 % -9.54 % 5.37 %

Quick ratio ranking by company, industry and sector >> Back to PRQR Financial Strength Comparisons >> Go to Compare PRQR Quick Ratio to its Competitors

  News about Proqr Therapeutics N v Quick Ratio

LEIDEN, the Netherlands, 2024 ProQR Therapeutics N.V. a company at the forefront of RNA therapies, is...

ProQR Joins Cantor Global Healthcare Conference Amid Stable Market Performance LEIDEN, the Netherlands, 2024 ProQR Therapeutics N.V. a company at the forefront of RNA therapies, is set to present at the 2024 Cantor Global Healthcare Conference, a prestigious event that gathers key stakeholders from across the healthcare industry. The company s participation underscores its ongoing commitment to advancing innovative treatments for genetic disorders.ProQR s webcast presentation is highly anticipated, given the company s influential role in the biopharmaceutical sector. Investors, industry experts, and researchers are keen to hear about ProQR’s latest advancements, strategic initiatives, and future outlook.

On the trailing twelve months basis In spite of the year on year decrease in PRQR's Current Liabilities to $36.33 millions, cumulative Quick Ratio to 2.85 below the PRQR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 494 other companies have achieved higher Quick Ratio than Proqr Therapeutics N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3497 to 4623.

Explain Quick Ratio?
How much Cash & cash equivalents PRQR´s has?
What are PRQR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 495
Healthcare Sector # 997
Within the Market # 4623


trailing twelve months Quick Ratio Statistics
High Average Low
8.58 4.62 2.85
(Dec 31 2019)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Atea Pharmaceuticals Inc   7.75 $ 301.830  Millions$ 38.941  Millions
Anixa Biosciences Inc   7.71 $ 15.174  Millions$ 1.967  Millions
Shattuck Labs Inc   7.68 $ 54.192  Millions$ 7.052  Millions
Scynexis Inc   7.62 $ 40.031  Millions$ 5.251  Millions
Avalo Therapeutics Inc   7.60 $ 98.373  Millions$ 12.940  Millions
Milestone Pharmaceuticals Inc   7.58 $ 105.960  Millions$ 13.979  Millions
Acrivon Therapeutics Inc   7.57 $ 118.582  Millions$ 15.664  Millions
Annovis Bio Inc   7.54 $ 19.532  Millions$ 2.591  Millions
Newamsterdam Pharma Company N v   7.40 $ 636.241  Millions$ 86.036  Millions
Adicet Bio Inc   7.36 $ 158.530  Millions$ 21.531  Millions
Novabridge Biosciences  7.33 $ 210.842  Millions$ 28.781  Millions
Day One Biopharmaceuticals Inc   7.29 $ 441.113  Millions$ 60.522  Millions
Eledon Pharmaceuticals Inc   7.27 $ 133.336  Millions$ 18.344  Millions
Marker Therapeutics inc   7.07 $ 16.068  Millions$ 2.274  Millions
Camp4 Therapeutics Corporation  7.06 $ 109.517  Millions$ 15.514  Millions
Barinthus Biotherapeutics Plc  7.03 $ 70.456  Millions$ 10.018  Millions
Xenon Pharmaceuticals Inc   7.02 $ 548.886  Millions$ 78.167  Millions
Stablecoin Development Corporation  6.97 $ 7.958  Millions$ 1.142  Millions
Centessa Pharmaceuticals Plc  6.86 $ 294.580  Millions$ 42.935  Millions
Tonix Pharmaceuticals Holding Corp   6.73 $ 207.637  Millions$ 30.837  Millions
Zentalis Pharmaceuticals Inc   6.73 $ 245.893  Millions$ 36.559  Millions
An2 Therapeutics Inc   6.65 $ 58.001  Millions$ 8.720  Millions
Actinium Pharmaceuticals Inc  6.62 $ 47.998  Millions$ 7.247  Millions
Gain Therapeutics inc  6.45 $ 20.838  Millions$ 3.233  Millions
Nuvation Bio Inc   6.44 $ 529.211  Millions$ 82.231  Millions
Vistagen Therapeutics Inc   6.38 $ 80.482  Millions$ 12.612  Millions
Arcturus Therapeutics Holdings Inc   6.35 $ 230.909  Millions$ 36.379  Millions
Wave Life Sciences Ltd   6.33 $ 602.068  Millions$ 95.065  Millions
Korro Bio Inc   6.30 $ 75.156  Millions$ 11.937  Millions
Rocket Pharmaceuticals Inc   6.25 $ 188.929  Millions$ 30.206  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.